Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.

Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M.

Neurology. 2004 Apr 13;62(7):1066-72.

PMID:
15079003
2.

Small fiber dysfunction predominates in Fabry neuropathy.

Dütsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ.

J Clin Neurophysiol. 2002 Dec;19(6):575-86.

PMID:
12488789
3.

Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.

Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO.

Muscle Nerve. 2003 Dec;28(6):703-10.

PMID:
14639584
4.

Neurological complications in Fabry disease.

Dütsch M, Hilz MJ.

Rev Med Interne. 2010 Dec;31 Suppl 2:S243-50. doi: 10.1016/S0248-8663(10)70021-7.

PMID:
21211673
5.

Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.

Thofehrn S, Netto C, Cecchin C, Burin M, Matte U, Brustolin S, Nunes AC, Coelho J, Tsao M, Jardim L, Giugliani R, Barros EJ.

Ren Fail. 2009;31(9):773-8. doi: 10.3109/08860220903150296.

PMID:
19925283
6.

Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.

Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A; FOS European Investigators.

Clin J Pain. 2007 Jul-Aug;23(6):535-42.

PMID:
17575495
7.

Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy.

Schiffmann R.

Acta Neurol Belg. 2006 Jun;106(2):61-5. Review.

PMID:
16898255
8.

Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.

Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA, Marchini F, Martinelli F, Bianco F, Panichi V, Procaccini DA, Ragazzoni E, Serra A, Soliani F, Spinelli L, Torti G, Veroux M, Cianciaruso B, Cagnoli L.

Nephrol Dial Transplant. 2008 May;23(5):1628-35. Epub 2007 Dec 5.

9.

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators.

J Med Genet. 2005 Mar;42(3):247-52.

10.

Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.

Üçeyler N, He L, Schönfeld D, Kahn AK, Reiners K, Hilz MJ, Breunig F, Sommer C.

J Peripher Nerv Syst. 2011 Dec;16(4):304-14. doi: 10.1111/j.1529-8027.2011.00365.x.

PMID:
22176145
11.

Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Schaefer RM, Tylki-Szymańska A, Hilz MJ.

Drugs. 2009 Nov 12;69(16):2179-205. doi: 10.2165/11318300-000000000-00000. Review.

PMID:
19852524
12.

Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in patients with Fabry disease.

Tavakoli M, Marshall A, Thompson L, Kenny M, Waldek S, Efron N, Malik RA.

Muscle Nerve. 2009 Dec;40(6):976-84. doi: 10.1002/mus.21383.

PMID:
19902546
13.

Physiological characterization of neuropathy in Fabry's disease.

Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJ, Dambrosia JM, Barton NW, Schiffmann R.

Muscle Nerve. 2002 Nov;26(5):622-9.

PMID:
12402283
14.

Fabry disease: overall effects of agalsidase alfa treatment.

Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A.

Eur J Clin Invest. 2004 Dec;34(12):838-44.

PMID:
15606727
15.

Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey.

Hajioff D, Hegemann S, Conti G, Beck M, Sunder-Plassmann G, Widmer U, Mehta A, Keilmann A.

Eur J Clin Invest. 2006 Sep;36(9):663-7. Erratum in: Eur J Clin Invest. 2007 Oct;37(10):828. Hegemannn, S [corrected to Hegemann, S].

PMID:
16919050
16.

Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.

Torvin Møller A, Winther Bach F, Feldt-Rasmussen U, Rasmussen A, Hasholt L, Lan H, Sommer C, Kølvraa S, Ballegaard M, Staehelin Jensen T.

Pain. 2009 Sep;145(1-2):237-45. doi: 10.1016/j.pain.2009.06.032. Epub 2009 Aug 7.

PMID:
19665302
17.

Head-impulse testing in Fabry disease--vestibular function in male and female patients.

Palla A, Widmer U, Straumann D.

Acta Paediatr Suppl. 2003 Dec;92(443):38-42; discussion 27.

PMID:
14989465
18.

Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease.

Jardim LB, Gomes I, Netto CB, Nora DB, Matte US, Pereira F, Burin MG, Kalakun L, Giugliani R, Becker J.

J Inherit Metab Dis. 2006 Oct;29(5):653-9. Epub 2006 Jul 27.

PMID:
16972173
19.

Metronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapy.

Hilz MJ, Koehn J, Kolodny EH, Brys M, Moeller S, Stemper B.

J Hypertens. 2011 Dec;29(12):2387-94. doi: 10.1097/HJH.0b013e32834c31db.

PMID:
21970939
20.

A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.

Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A, Moore D.

Health Technol Assess. 2006 Jun;10(20):iii-iv, ix-113. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk